Pro Medicus (ASX: PME) – Pro Medicus Signs $23M St Luke’s Contract

Pro Medicus Limited has secured a A$23 million, seven-year contract with St. Luke’s Health System, a significant expansion of its footprint in the North American healthcare technology market. The agreement, announced on 12 August 2026, will deploy the company’s cloud-based Visage 7 enterprise imaging platform across one of Idaho’s largest health systems, which operates 10 medical centers spanning southern Idaho, eastern Oregon, and northern Nevada. St. Luke’s is the state’s largest private employer and a not-for-profit healthcare provider, making it a material win for Pro Medicus in the competitive U.S. health IT space.

The contract represents a validation of Pro Medicus’ strategic pivot toward cloud-based medical imaging solutions. St. Luke’s will implement both Visage 7 Viewer and Visage 7 Workflow through the company’s proven cloud deployment process, with implementation planned for Q1 2027. The transaction-based licensing model is particularly noteworthy for investors, as it carries potential revenue upside beyond the headline contract value. This means the actual value to Pro Medicus could exceed the initial A$23 million figure if utilisation rates or ancillary services exceed current projections, providing optionality that pure fixed-fee contracts would not offer.

For investors, this win signals continued momentum in the company’s North American expansion. Pro Medicus CEO Dr Sam Hupert noted that St. Luke’s joins a growing list of large healthcare systems adopting fully cloud-based platforms, a market shift that favours the company’s CloudPACS strategy. The CEO also highlighted a strong pipeline spanning multiple customer segments, from large academic medical centers through mid-sized integrated delivery networks like St. Luke’s to private imaging groups, which collectively represent what the company views as the largest addressable market among competing medical imaging platforms. This diversified pipeline suggests Pro Medicus is well-positioned across multiple customer tiers rather than dependent on any single segment.

The timing matters for healthcare IT investment patterns. Healthcare budgets remain under pressure across the U.S., yet major health systems continue to invest in modernisation and cloud migration. St. Luke’s decision to transition suggests confidence in both the economic case for cloud-based imaging and in Visage 7’s capability to support large, geographically dispersed health networks. A successful implementation at St. Luke’s could serve as a reference site for other similar-sized systems evaluating cloud platforms, potentially accelerating future contract wins.

The scheduled Q1 2027 go-live provides a near-term milestone for the market to monitor. Revenue recognition will likely occur post-deployment, so while the contract was announced in August 2026, material revenue flow depends on successful execution and transaction volumes across St. Luke’s sites. Investors should track the company’s guidance and pipeline commentary to gauge whether the St. Luke’s win is part of a sustained acceleration. This announcement is price sensitive and flagged as material by the ASX.

View the full ASX announcement (PDF)

About Pro Medicus Limited (ASX: PME)

Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.

If you would like to discuss this announcement, request a callback or call us on 1300 889 603.